IL2 and melanoma: Prior to2010, the only US Food and Drug Administration (FDA)-approved therapies for stage IV melanoma werehigh-dose interleukin-2 and dacarbazine, both of which were approved based on phase II clinical trial data.In 2011, two therapies were approved by the FDA for use in unresectable stage III and IV melanoma, basedon improvements in overall survival noted in phase III trials.